Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for PTEN and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PTEN and 80,000+ other tickers.
See exactly how PTEN's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PTEN and 80,000+ other tickers.
Patterson-UTI Energy, Inc. (PTEN) is a key provider of onshore contract drilling services for oil and natural gas exploration and production companies. Its operations span across the United States and international markets. The company's diverse business model is structured around three primary segments: 1. Contract Drilling Services: This division delivers drilling solutions predominantly in prominent U.S. basins such as West Texas, Appalachia, the Rockies, Oklahoma, and both South and East Texas, alongside operations in Colombia. As of late 2021, its robust fleet comprised 192 marketable…
Oil's rally above $80 could lift demand for Patterson-UTI's drilling services and TechnipFMC's onshore and offshore technologies.
Patterson-UTI (PTEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Escalating U.S.-Iran tensions are lifting oil prices, while HAL and PTEN remain below industry EV/EBITDA averages after strong rallies.
IRVING, Texas, July 14, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced it will offer in-house PTEN immunohistochemistry (IHC) testing following the recent FDA approval of a biomarker-guided therapy and companion diagnostic assay. This testing is designed to help identify patients with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously known as metastatic hormone-sensitive prostate cancer) who are eligible for the newly approved biomarker-guided therapy, representing a significant advancement in precision oncology for this disease.
HOUSTON, TX / ACCESS Newswire / July 9, 2026 / PATTERSON-UTI ENERGY, INC. (NASDAQ:PTEN) will host a conference call on Thursday, July 30, 2026, at 9:00 a.m.